LexDanaLexDanabeta
Inventor

James T. Dalton

Inventor
Ann Arbor, MI, US

Overview

95→
Patents
2000–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 95 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
C07CAcyclic or carbocyclic compounds22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C07DHeterocyclic compounds13%
C07BGeneral methods of organic chemistry3%
A23KFodder2%
B60RVehicles, vehicle fittings, or vehicle parts, not otherwise provided for2%
B62JCycle saddles or seats2%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
11,090,283Solid forms of selective androgen receptor modulators202111,084,811Compounds for treatment of cancer202110,865,196Compounds for treatment of cancer202010,849,873Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy202010,662,148Selective androgen receptor modulator and methods of use thereof202010,597,354Selective androgen receptor degrader (SARD) ligands and methods of use thereof202010,441,570Selective androgen receptor degrader (SARD) Ligands and methods of use thereof201910,314,807Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)201910,300,037SARMs and method of use thereof201910,301,285Compounds for treatment of cancer201910,258,596Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)201910,155,728Compounds for treatment of cancer201810,093,613Selective androgen receptor degrader (SARD) ligands and methods of use thereof201810,053,418Selective androgen receptor modulator and methods of use thereof201810,035,763Selective androgen receptor degrader (SARD) ligands and methods of use thereof201810,017,471Selective androgen receptor degrader (SARD) ligands and methods of use thereof201810,010,521SARMs and method of use thereof20189,981,915Compounds for treatment of cancer20189,969,683Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)20189,889,110'Selective androgen receptor modulator for treating hormone-related conditions'20189,884,038'Selective androgen receptor modulator and methods of use thereof'20189,844,528SARMs and method of use thereof20179,834,507Selective androgen receptor degrader (SARD) ligands and methods of use thereof20179,814,698'Selective androgen receptor degrader (SARD) ligands and methods of use thereof'20179,815,776'Selective androgen receptor degrader (SARD) ligands and methods of use thereof'20179,744,149'Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)'20179,730,908'SARMs and method of use thereof'20179,622,992'Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)'20179,623,021'Nuclear receptor binding agents'20179,624,161'Estrogen receptor ligands and methods of use thereof'20179,604,931'Nuclear receptor binding agents'20179,604,916'Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)'20179,493,403'Treating androgen decline in aging male (ADAM)-associated conditions with SARMs'20169,447,049'Compounds for treatment of cancer'20169,427,418'Estrogen receptor ligands and methods of use thereof'20169,409,856'Estrogen receptor ligands and methods of use thereof'20169,334,242'Compounds for treatment of cancer'20169,278,914'SARMs and method of use thereof'20169,150,501'Solid forms of selective androgen receptor modulators'20159,078,888'Nuclear receptor binding agents'20159,051,267'Estrogen receptor ligands and methods of use thereof'20159,029,408'Compounds for treatment of cancer'20158,853,266'Selective androgen receptor modulators for treating diabetes'20148,846,756'Substituted acylanilides and methods of use thereof'20148,822,513'Compounds for treatment of cancer'20148,791,158'Methods of treating meibomian gland dysfunction'20148,669,286'SARMs and method of use thereof'20148,637,706'Nuclear receptor binding agents'20148,592,465'Compounds for treatment of cancer'20138,563,606'Solid forms of selective androgen receptor modulators'20138,546,451'Estrogen receptor ligands and methods of use thereof'20138,445,534'Treating androgen decline in aging male (ADAM)-associated conditions with SARMs'20138,426,465'Substituted acylanilides and methods of use thereof'20138,318,812'Therapeutic agents for the treatment of lymphoid malignancies'20128,309,603'SARMs and method of use thereof'20128,158,828'Nuclear receptor binding agents'20128,110,562'Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof'20128,088,828'Treating benign prostate hyperplasia with SARMS'20128,080,682'Substituted acylanilides and methods of use thereof'20118,008,348'Treating muscle wasting with selective androgen receptor modulators'20117,977,386'Solid forms of selective androgen receptor modulators'20117,968,603'Solid forms of selective androgen receptor modulators'20117,919,647'Selective androgen receptor modulators and methods of use thereof'20117,855,229'Treating wasting disorders with selective androgen receptor modulators'20107,803,970'Multi-substitued selective androgen receptor modulators and methods of use thereof'20107,776,921'Treating benign prostate hyperplasia with SARMS'20107,772,433'SARMS and method of use thereof'20107,759,520'Synthesis of selective androgen receptor modulators'20107,741,371'Selective androgen receptor modulators and methods of use thereof'20107,705,182'Multi-substituted selective androgen receptor modulators and methods of use thereof'20107,662,842'Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents'20107,645,898'Selective androgen receptor modulators and method of use thereof'20107,622,503'Selective androgen receptor modulators and methods of use thereof'20097,595,402'Prodrugs of selective androgen receptor modulators and methods of use thereof'20097,547,728'Treating muscle wasting with selective androgen receptor modulators'20097,518,013'Selective androgen receptor modulators'20097,344,700'Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy'20087,307,093'Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof'20077,253,210'Methylene-bridged selective androgen receptor modulators and methods of use thereof'20077,214,693'Heterocyclic selective androgen receptor modulators and methods of use thereof'20077,205,437'Selective androgen receptor modulators'20077,129,377'Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer'20067,041,844'Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer'20067,026,500'Halogenated selective androgen receptor modulators and methods of use thereof'20067,022,870'N-bridged selective androgen receptor modulators and methods of use thereof'20066,998,500'Selective androgen receptor modulators and methods of use thereof'20066,995,284'Synthesis of selective androgen receptor modulators'20066,875,757'LPA receptor agonists and antagonists and methods of use'20056,838,484'Formulations comprising selective androgen receptor modulators'20056,569,896'Selective androgen receptor modulators and methods of use thereof'20036,492,554'Selective androgen receptor modulators and methods of use thereof'20026,482,861'Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer'20026,160,011'Non-steroidal agonist compounds and their use in male hormone therapy'20006,071,957'Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer'20006,019,957'Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2002Based in Memphis, TN, US· patent location history
2002–2013Based in Columbus, OH, US· patent location history
2005–2016Patents assigned to UNIV TENNESSEE RES FOUNDATION (38)· patent assignee history
2006–2017Based in Upper Arlington, OH, US· patent location history
2009–2021Patents assigned to GTX INC (37)· patent assignee history
2011–2018Patents assigned to DALTON JAMES T (21)· patent assignee history
2011–2018Patents assigned to MILLER DUANE D (15)· patent assignee history
2011–2018Based in Lakeland, TN, US· patent location history
2016–2021Patents assigned to UNIV TENNESSEE RES FOUND (24)· patent assignee history
2016–2021Based in Ann Arbor, MI, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
UNIV TENNESSEE RES FOUNDATION382005–2016
GTX INC372009–2021
UNIV TENNESSEE RES FOUND242016–2021
DALTON JAMES Tself212011–2018
MILLER DUANE D152011–2018
Locations
LocationPatentsSpan
Ann Arbor, MI, US272016–2021
Lakeland, TN, US272011–2018
Upper Arlington, OH, US242006–2017
Columbus, OH, US122002–2013
Memphis, TN, US42000–2002